Administration of FGF21 protein, FGF21 analogs, or delivery of FGF21 by adenovirus into rodent models of NAFLD prevented hepatosteatosis with the suppression of de novo lipogenesis and the increased fat oxidation in the liver 24-27. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.